The accelerated adoption of SHINGRIX has led to an unprecedented level of demand.
Healthcare professionals have adopted SHINGRIX and are now vaccinating against shingles at a much higher rate than in previous years.
GSK projects to bring significantly more doses of SHINGRIX into the market in the second half of the year than in the first half of the year.
GSK expects to consistently release doses of SHINGRIX into the market every 2-3 weeks to provide a more predictable and reliable supply experience. As healthcare professionals are vaccinating with SHINGRIX at an unprecedented rate, ordering limits and allocations should still be expected and individual customer resupply experiences will vary.
While demand still exceeds supply, the increased and consistent supply should provide reassurance that patients will have an opportunity to complete the 2-dose series within the 2-6 month dosing window.
There have been no manufacturing issues.
Thank you again for your partnership and commitment to protecting appropriate patients from shingles. Please do not hesitate to contact GSK with any further questions. You may reach us at 1-800-772-9292 or contact your GSK Vaccines Representative today.
SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.
SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).
All trademarks are the property of their respective owners.
1009805R0 September 2018